Susquehanna International Group, LLP Alzamend Neuro, Inc. Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	BUY	$0.37 - $0.71 $284 - $545	768 Added 2.16%	36,281 $15,000
Q4 2022 Feb 14, 2023	BUY	$0.53 - $222.0 $18,821 - $7.88 Million	35,513 New	35,513 $19,000
Q2 2022 Aug 15, 2022	BUY	$0.82 - $1.2 $21,307 - $31,182	25,985 Added 44.83%	83,950 $73,000
Q1 2022 May 16, 2022	SELL	$0.91 - $2.23 $130,858 - $320,674	-143,800 Reduced 71.27%	57,965 $71,000
Q4 2021 Feb 14, 2022	BUY	$1.9 - $3.08 $208,029 - $337,226	109,489 Added 118.65%	201,765 $383,000
Q3 2021 Nov 15, 2021	BUY	$2.28 - $7.68 $80,360 - $270,689	35,246 Added 61.8%	92,276 $284,000
Q2 2021 Aug 11, 2021	BUY	$8.12 - $13.5 $463,083 - $769,905	57,030 New	57,030 $498,000

Ticker ALZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 95,481,800
Market Cap $122M
Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.